Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

New mass spectrometry method to simultaneously quantify several tau species in blood

Quantification of tau peptides in blood samples using a new mass spectrometry method suggests that individual phosphorylated tau peptides have distinct patterns of emergence in Alzheimer’s disease and differential associations with amyloid and tau pathologies. This method has the potential to stage patients along the disease continuum and for clinical trials.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Association of plasma p-tau variants with amyloid PET and tau PET.


  1. Ossenkoppele, R. et al. Tau biomarkers in Alzheimer’s disease: towards implementation in clinical practice and trials. Lancet Neurol. 21, 726–734 (2022). This review describes the basics of tau pathology in AD and provides an update on tau biomarkers (PET, cerebrospinal fluid and plasma).

    Article  CAS  PubMed  Google Scholar 

  2. van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. 388, 9–21 (2023). This paper reports the results from the successful phase 3 clinical trial of a monoclonal antibody that binds with high affinity to Aβ soluble protofibrils.

    Article  PubMed  Google Scholar 

  3. Ashton, N. J. et al. Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring. Nat. Med. 28, 2555–2562 (2022). This paper highlights p-tau217 as a surrogate marker of disease progression in preclinical and prodromal AD.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Karikari, T. K. et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat. Rev. Neurol. 18, 400–418 (2022). This review summarizes the performance and potential use of blood p-tau biomarkers in AD.

    Article  CAS  PubMed  Google Scholar 

  5. Gobom, J. et al. Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum. Mol. Neurodegener. 17, 81 (2022). This paper reports the MS method to quantify several tau peptides that was the precursor of the approach used in the current study.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Pontecorvo, M. J. et al. Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 79, 1250–1259 (2022). This paper reports the results from a clinical trial in which participants were selected on the basis of intermediate tau PET burden.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Montoliu-Gaya, L. et al. Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. Nat. Aging, (2023).

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

New mass spectrometry method to simultaneously quantify several tau species in blood. Nat Aging 3, 638–639 (2023).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing